Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis

OBJECTIVE: To determine the duration of clinical benefit among patients with psoriatic arthritis (PsA) discontinuing tumour necrosis factor inhibitor (TNFi) therapy while in low disease activity (LDA), and to identify patient characteristics associated with prolonged clinical benefit. METHODS: We pe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:RMD Open
Main Authors: Huynh, D H, Boyd, T A, Etzel, C J, Cox, V, Kremer, J, Mease, P, Kavanaugh, A
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2017
Assuntos:
Psoriatic Arthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5255890/
https://ncbi.nlm.nih.gov/pubmed/28123783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2016-000395
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados